Regular monitoring and management of cardiovascular adverse events are essential for patients receiving long-term tyrosine kinase inhibitor therapy.
No takes yet. Share an insight, caveat, or question.
Supports CV monitoring in long-term TKI recipients; leaves open optimal protocols without prospective validation.
Lenihan et al. (2013) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: